WO2023021494 - COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR
National phase entry:
Publication Number
WO/2023/021494
Publication Date
23.02.2023
International Application No.
PCT/IB2022/057857
International Filing Date
22.08.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR
[French]
COMPOSITIONS ET PROCÉDÉS POUR RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ANTI-VIRAL
Applicants **
RUDD, Christopher E.
136 Chemin Broughton
Montreal West, Québec H4X 1K3, CA
Inventors
RUDD, Christopher E.
136 Chemin Broughton
Montreal West, Québec H4X 1K3, CA
Priority Data
63/235,647
20.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4785 | |
| EPO | Filing, Examination | 35315 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 22910 |
Total: 64176 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are Chimeric Antigen Receptor (CAR) polypeptides, polynucleotides encoding the CARs, host cells containing or expressing the CARs and polynucleotides and methods of use to treat viral infections such as COVID or cancers in patients in need thereof.[French]
L'invention concerne des polypeptides de récepteur antigénique chimérique (CAR), des polynucléotides codant pour les CAR, des cellules hôtes contenant ou exprimant les CAR et les polynucléotides et des procédés d'utilisation pour traiter des infections virales telles que COVID ou des cancers chez des patients en ayant besoin.